- Since 2009, EBI team has discovered novel inhibitors against ALK, BRAF, MEK, EZH2, and BTK.

- Two BTK inhibitors have been licensed to TG Therapeutics for a total value of $347 million.

- EZH2 and BTK inhibitors are currently under clinical development in multiple countries.